Tocagen Inc.

Industry · 8 registered clinical trials.

Status	Trial	Phase	Started
Withdrawn	A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8 Bladder Cancer	Phase 1	2019-12-01
Withdrawn	A Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With New Newly Diagnosed High Grade Glioma (HGG)	Phase 1	2017-01-01
Terminated	A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or L Colorectal Cancer, Triple Negative Breast Cancer, Pancreatic Cancer	Phase 1	2016-07-01
Terminated	The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma Glioblastoma Multiforme, Anaplastic Astrocytoma	Phase 2 / Phase 3	2015-11-30
Completed	Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brai Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma	Phase 1	2014-02-01
Completed	Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Re Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma	Phase 1	2012-02-01
Terminated	A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511 Glioblastoma Multiforme, Astrocytoma, Gliomas, Malignant	Phase 1	2011-02-01
Completed	A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Mal Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma	Phase 1	2010-07-01